- Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
EMN 18 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib...
168
- Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
LocoMMotion Relapsed & Refractory Multiple Myeloma NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed...
159
- Dec 20, 2018
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)
NCT03562169: Phase 3: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) NCT03562169:...
73
- Dec 7, 2018
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
Myeloma XI The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide...
385
- Dec 13, 2016
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono...
86
- Dec 31, 2015
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in...
644